The recent Emergency Use Authorization issued by the Food and Drug Administration expands access to home collection testing for minors to allow a wider population to understand their health status and contain the spread of Coronavirus among children.
Following the May 2020 FDA EUA for the LetsGetChecked Coronavirus (COVID-19) home collection test and the March 2021 FDA EUA for direct-to-consumer purchasing without a prescription, this updated authorization for minors will support a safe return to school, play, travel, and more.
Using the company's end-to-end model, LetsGetChecked offers a FDA EUA authorized Coronavirus (COVID-19) home collection testing solution.
The Coronavirus (COVID-19) home collection test incorporates a nasal swab and PCR lab analysis with convenient and secure results in 24-72 hours after lab receipt. Unlike serology tests that detect the presence of antibodies or viral antigens, the test determines the presence or absence of SARS-CoV-2 viral RNA.
Under this re-issued LetsGetChecked authorization, children aged 12 to 18 years can self collect under adult supervision, and samples from children two to 11 years can be collected with adult assistance.
The ability to test minors for Coronavirus using LetsGetChecked's platform will provide parents and guardians increased peace of mind as the country reopens, and children gather in-person and return to the classroom.
LetsGetChecked is a virtual care company that allows customers to manage their health from home, providing direct access to telehealth services, pharmacy, and at-home diagnostics for a wide range of health conditions including Sexual Health, Cholesterol, Diabetes, Thyroid, Coronavirus (COVID-19), and more.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval